People with COPD in the US have a reason to celebrate this morning. Daliresp, known as Daxas in other countries, has just been approved in the USA by the Food and Drug Administration.
Daliresp is the first drug of its kind to be approved for maintenance treatment of COPD. It is a phosphodiesterase 4 (PDE4) inhibitor, a type of drug that blocks PDE4, an enzyme that is overproduced in people who have COPD or asthma causing inflammation in the lungs.
In a previous blog post, I wrote about how studies have shown that Daliresp improves lung function and reduces the number of COPD exacerbations in patients who have moderate to severe forms of COPD. Studies have also suggested that Daliresp improves pre-bronchodilator FEV1 across the board by as much as 80 milliliters and reduces COPD exacerbations by as much as 17 percent.
For those of you in the US who have been waiting for a new drug to be approved by the FDA that may help improve your COPD symptoms, this one shows significant promise. Talk to your health care provider today to see if Daliresp is an appropriate addition to your COPD treatment regimen.
According to Forest Laboratories, Daliresp will be available in the second quarter of 2011. For more information call (800) 678-1605 ext. 66297 or visit Forest Laboratories.